Human glioblastoma in mouse

Publications

The following includes selected recent publications from our lab.

A Roadmap of CAR-T-Cell Therapy in Glioblastoma: Challenges and Future Perspectives [Review]

Montoya M, Gallus M, Phyu S, Haegelin J, de Groot J, Okada H.

Cells. 2024 Apr 23; 13 (9): 726. doi: 10.3390/cells13090726. PMID: 38727262; PMCID: PMC11083543.
PubMed Link >

Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment

Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H

JCI Insight. 2024 Apr 8; 9 (7): e177141. doi: 10.1172/jci.insight.177141. PMID: 38386420; PMCID: PMC11128202.
PubMed Link >

Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma

Nejo T, Wang L, Leung KK, Wang A, Lakshmanachetty S, Gallus M, Kwok DW, Hong C, Chen LH, Carrera DA, Zhang MY, Stevers NO, Maldonado GC, Yamamichi A, Watchmaker PB, Naik A, Shai A, Phillips JJ, Chang SM, Wiita AP, Wells JA, Costello JF, Diaz AA, Okada H

Sci Rep. 2024 Mar 16; 14 (1): 6362. doi: 10.1038/s41598-024-56684-0. PMID: 38493204; PMCID: PMC10944514.
PubMed Link >

A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas

Saijo A, Ogino H, Butowski NA, Tedesco MR, Gibson D, Watchmaker PB, Okada K, Wang AS, Shai A, Salazar AM, Molinaro AM, Rabbitt JE, Shahin M, Perry A, Clarke JL, Taylor JW, Daras M, Oberheim Bush NA, Hervey-Jumper SL, Phillips JJ, Chang SM, Hilf N, Mayer-Mokler A, Keler T, Berger MS, Okada H

Neuro Oncol. 2024 Feb 2; 26 (2): 335-347. doi: 10.1093/neuonc/noad185. PMID: 37758193; PMCID: PMC10836773.
PubMed Link >

Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens

Kwok DW, Stevers NO, Nejo T, Chen LH, Etxeberria I, Jung J, Okada K, Cove MC, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Wu SH, Ramos E, Yamamichi A, Liu J, Watchmaker P, Ogino H, Saijo A, Du A, Grishanina N, Woo J, Diaz A, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA, Costello JF, Okada H

bioRxiv. 2023 Oct 20; doi: 10.1101/2023.10.19.563178. PMID: 37904942; PMCID: PMC10614978.
PubMed Link >

Glioma-neuronal circuit remodeling induces regional immunosuppression

Nejo T, Krishna S, Jimenez C, Yamamichi A, Young JS, Lakshmanachetty S, Chen T, Phyu SSS, Ogino H, Watchmaker P, Diebold D, Choudhury A, Daniel AGS, Raleigh DR, Hervey-Jumper SL, Okada H.

bioRxiv. 2023 Aug 6; doi: 10.1101/2023.08.04.548295. PMID: 37577659; PMCID: PMC10418167.
PubMed Link >

Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma [Review]

Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H.

Cancers. 2023 Jul 22; 15 (14): 3726. doi: 10.3390/cancers15143726. PMID: 37509387; PMCID: PMC10378701.
PubMed Link >

Future development of chimeric antigen receptor T cell therapies for patients suffering from malignant glioma

Watchmaker PB, Colton M, Pineo-Cavanaugh PL, Okada H.

Curr Opin Oncol.. 2022 Nov 1; 34 (6): 661-669. doi: 10.1097/CCO.0000000000000877. PMID: 35855503; PMCID: PMC9560977.
PubMed Link >

Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.

Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, Tron AE, Hyer ML, Montoya M, Mende AL, Nejo T, Downey KM, Diebold D, Lu M, Nicolay B, Okada H. 

J Immunother Cancer.. 2022 May 1; 10 (5): e004644. doi: 10.1136/jitc-2022-004644. PMID: 35606087; PMCID: PMC9174833.
PubMed Link >

Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas.

Ogino H, Taylor JW, Nejo T, Gibson D, Watchmaker PB, Okada K, Saijo A, Tedesco MR, Shai A, Wong CM, Rabbitt JE, Olin MR, Moertel CL, Nishioka Y, Salazar AM, Molinaro AM, Phillips JJ, Butowski NA, Clarke JL, Oberheim Bush NA, Hervey-Jumper SL, Theodosopoulos P, Chang SM, Berger MS, Okada H. 

J Clin Invest.. 2022 Feb 1; 132 (3): e151239. doi: 10.1172/JCI151239. PMID: 34882581; PMCID: PMC8803342.
PubMed Link >

Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.

Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H. 
 

Neuro Oncol. 2021 Aug 4; doi: 10.1093/neuonc/noab182..
PubMed Link >

IFN-γ- and IL-17-producing CD8+ T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity.

Ohkuri T, Kosaka A, Ikeura M, Salazar AM, Okada H. 

J Immunother Cancer. 2021 Jun 1; 9(6):e002426. doi: 10.1136/jitc-2021-002426. PMID: 34193567; PMCID: PMC8246372.
PubMed Link >
Cover of Science Translational Medicine, April 2021

SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma

Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, Downey KM, Yu W, Carrera DA, Celli A, Cho J, Briones JD, Duecker JM, Goretsky YE, Dannenfelser R, Cardarelli L, Troyanskaya O, Sidhu SS, Roybal KT, Okada H, Lim WA.

Sci Transl Med. 2021 Apr 28; 13 (591): eabe7378. doi: 10.1126/scitranslmed.abe7378.
PubMed Link >

The evolution of alternative splicing in glioblastoma under therapy

Wang L, Shamardani K, Babikir H, Catalan F, Nejo T, Chang S, Phillips JJ, Okada H, Diaz AA

Genome Biol. 2021 Jan 26; 22 (1): 48. doi: 10.1186/s13059-021-02259-5. PMID: 33499924; PMCID: PMC7835670.
PubMed Link >

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma

Mueller S, Taitt JM, Villanueva-Meyer JE, Bonner ER, Nejo T, Lulla RR, Goldman S, Banerjee A, Chi SN, Whipple NS, Crawford JR, Gauvain K, Nazemi KJ, Watchmaker PB, Almeida ND, Okada K, Salazar AM, Gilbert RD, Nazarian J, Molinaro AM, Butterfield LH, Prados MD, Okada H.

J Clin Invest. 2020 Dec 1; 130 (12): 6325-6337. doi: 10.1172/JCI140378. PMID: 35703183; PMCID: PMC9203080.
PubMed Link >